Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
STAB Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: January 04, 2023
Report Source: 2022 3rd Quarter Report
Statera Biopharma Inc. Stock Analysis STAB
United States Health Care Nano Cap Report: Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Through its developmental Advanced Immunomodulating Multi-Component System (AIMS) platform, it has advanced several late-stage developmental product candidates. AIMS allows it to integrate multiple factors that define a superior composition, including key pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. The firm has a platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. The company has clinical and preclinical programs for Crohn’s disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis.
Read More Statera Biopharma Inc (STAB) Chart
Key Statistics of Statera Biopharma Inc (STAB)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
9324.00P/E Ratio (TTM)
-52 Week Range
Market Cap
7142.00Avg. Volume
3345.72Dividend Yield
-Financial Metrics & Statements of Statera Biopharma Inc (STAB)
FAQ's for Statera Biopharma Inc (STAB)
- According to Musaffa’s Shariah screening methodology, Statera Biopharma Inc (STAB) is currently classified as HALAL as of January 2023. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Statera Biopharma Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Statera Biopharma Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Statera Biopharma Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Statera Biopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Statera Biopharma Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.